These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 26632770

  • 1. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
    Rubio Gonzalez B, Zain J, Rosen ST, Querfeld C.
    Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
    [Abstract] [Full Text] [Related]

  • 2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [Abstract] [Full Text] [Related]

  • 3. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH, Olson LC, Magro CM.
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [Abstract] [Full Text] [Related]

  • 4. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH, Tensen CP, van der Stoop PM, van Oostveen HW, Lund M, Scheper RJ, Willemze R.
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS).
    Jothishankar B, Venkataraman G, Goldberg RC, Abdulla F.
    Ann Diagn Pathol; 2019 Dec; 43():151404. PubMed ID: 31629155
    [No Abstract] [Full Text] [Related]

  • 6. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
    Saed G, Fivenson DP, Naidu Y, Nickoloff BJ.
    J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
    [Abstract] [Full Text] [Related]

  • 7. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.
    Campbell JJ, Clark RA, Watanabe R, Kupper TS.
    Blood; 2010 Aug 05; 116(5):767-71. PubMed ID: 20484084
    [Abstract] [Full Text] [Related]

  • 8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb 05; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [Abstract] [Full Text] [Related]

  • 9. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
    Schlapbach C, Ochsenbein A, Kaelin U, Hassan AS, Hunger RE, Yawalkar N.
    J Am Acad Dermatol; 2010 Jun 05; 62(6):995-1004. PubMed ID: 20466174
    [Abstract] [Full Text] [Related]

  • 10. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE, Lefterova MI, Suarez CJ, Tavallaee M, Kim YH, Schrijver I, Kim J, Gratzinger D.
    Hum Pathol; 2015 Sep 05; 46(9):1382-9. PubMed ID: 26193796
    [Abstract] [Full Text] [Related]

  • 11. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
    Devata S, Wilcox RA.
    Am J Clin Dermatol; 2016 Jun 05; 17(3):225-37. PubMed ID: 26923912
    [Abstract] [Full Text] [Related]

  • 12. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS.
    J Invest Dermatol; 2009 May 05; 129(5):1165-73. PubMed ID: 18923451
    [Abstract] [Full Text] [Related]

  • 13. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S, Schulze HJ, Hallermann C.
    J Dtsch Dermatol Ges; 2014 Jul 05; 12(7):561-9. PubMed ID: 24889480
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
    Wong HK.
    G Ital Dermatol Venereol; 2008 Dec 05; 143(6):375-83. PubMed ID: 19169210
    [Abstract] [Full Text] [Related]

  • 16. Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre.
    De Masson A, Lazaridou I, Moins-Teisserenc H, Ram-Wolff C, Giustiniani J, Bagot M, Battistella M, Bensussan A.
    Immunol Lett; 2024 Aug 05; 268():106871. PubMed ID: 38801999
    [Abstract] [Full Text] [Related]

  • 17. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM, Cerroni L.
    Am J Dermatopathol; 2015 Feb 05; 37(2):115-21. PubMed ID: 25406852
    [Abstract] [Full Text] [Related]

  • 18. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
    Mehdi SJ, Moerman-Herzog A, Wong HK.
    BMC Cancer; 2021 May 03; 21(1):492. PubMed ID: 33941102
    [Abstract] [Full Text] [Related]

  • 19. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.
    Sausville EA, Worsham GF, Matthews MJ, Makuch RW, Fischmann AB, Schechter GP, Gazdar AF, Bunn PA.
    Hum Pathol; 1985 Nov 03; 16(11):1098-109. PubMed ID: 3876976
    [Abstract] [Full Text] [Related]

  • 20. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
    Luna DE, Shinohara MM.
    Curr Hematol Malig Rep; 2023 Jun 03; 18(3):83-88. PubMed ID: 37017872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.